Bristol-Myers Squibb Co (NYSE:BMY) insider Louis S. Schmukler sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the sale, the insider now owns 31,963 shares in the company, valued at approximately $1,807,827.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of NYSE BMY opened at $58.02 on Friday. The company has a quick ratio of 3.72, a current ratio of 3.83 and a debt-to-equity ratio of 1.37. Bristol-Myers Squibb Co has a 52 week low of $42.48 and a 52 week high of $58.46. The business’s 50 day moving average price is $52.90 and its 200 day moving average price is $48.19. The firm has a market cap of $91.88 billion, a P/E ratio of 14.58, a P/E/G ratio of 1.31 and a beta of 0.71.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The business had revenue of $6.01 billion for the quarter, compared to analyst estimates of $5.89 billion. During the same quarter in the prior year, the firm posted $1.09 EPS. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. As a group, research analysts expect that Bristol-Myers Squibb Co will post 4.33 earnings per share for the current year.
BMY has been the topic of a number of research analyst reports. Peel Hunt restated a “buy” rating on shares of Bristol-Myers Squibb in a research note on Tuesday, October 29th. UBS Group upped their target price on Bristol-Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a research report on Wednesday, October 23rd. Atlantic Securities upgraded Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price on the stock in a research report on Wednesday, August 14th. TheStreet upgraded Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research report on Wednesday, September 18th. Finally, Wolfe Research set a $66.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $56.64.
Institutional investors have recently added to or reduced their stakes in the business. Garrett Wealth Advisory Group LLC purchased a new stake in Bristol-Myers Squibb in the 3rd quarter worth approximately $26,000. Lenox Wealth Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 555.7% during the 3rd quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 539 shares during the period. Financial Gravity Wealth Inc. raised its stake in shares of Bristol-Myers Squibb by 101.2% during the 3rd quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 327 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Bristol-Myers Squibb by 52.9% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 665 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 230 shares during the period. Finally, 1 North Wealth Services LLC acquired a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $41,000. Institutional investors and hedge funds own 80.40% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Featured Story: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.